Partnering05

Numab offers its cutting-edge discovery engine to partners looking to develop innovative antibody-based therapeutics with multiple specificities, tailored half-lives, unrivaled potency, and ready to be taken into preclinical and process development. Our disclosed partners are 3SBio/Sunshine Guojian, Eisai, CStone, Ono, Kaken, and Tillotts.

Partners

3SBio / Sunshine Guojian

Eisai Co., Ltd.

CStone Pharmaceuticals

Ono Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

Tillotts Pharma AG

3SBio / Sunshine Guojian

3SBio is a fully integrated biotechnology company in China with market-leading biopharmaceutical franchises in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology. 3SBio is focusing on building an innovative product pipeline, currently with over 30 product candidates under development. 3SBio’s manufacturing capabilities include recombinant proteins, monoclonal antibodies and chemically synthesized molecules, with research and production centers in Shenyang, Shanghai, Hangzhou, Shenzhen and Cuomo, Italy. For more information about 3SBio, please visit: www.3sbio.com.

 

Sunshine Guojian was established in 2002 and is one of the first batch of innovative biopharmaceutical companies focusing on antibody drugs in China. It is the only domestic pharmaceutical company that has two launched therapeutic antibody drugs, and had emerged as a leader in antibody drug with its capabilities of independent R&D, industrialization and commercialization in China. Sunshine Guojian orients its R&D efforts primarily towards innovative therapeutic antibody drugs, and provides quality, safe and effective clinical solutions to the therapeutic areas of major diseases such as auto-immune diseases and tumors. Currently, Sunshine Guojian has 15 anti-body drug candidates (including 7 drug candidates in clinical and new drug registration stage and 8 drug candidates in pre-clinical stage) which are under different development stages, targeting tumor, auto-immune diseases and ophthalmological diseases. Most of those drug candidates are Category I biological products for therapeutic use or monoclonal antibodies, 2 of which are in application for launching, and 5 are in clinical stage. Sunshine Guojian may submit applications to both the China and the US Food and Drug Administration for some of those, or some of these drugs may be admitted for priority evaluation.

Eisai Co., Ltd.

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. They define their corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which they call their human health care (hhc) philosophy. With approximately 10,000 employees working across their global network of R&D facilities, manufacturing sites and marketing subsidiaries, they strive to realize their hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

As a global pharmaceutical company, their mission extends to patients around the world through their investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai, please visit: www.eisai.com.

CStone Pharmaceuticals

CStone Pharmaceuticals (HKEX:2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicine to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline with a strategic emphasis on immune-oncology combination therapies. With an experienced team, a rich pipeline, a robust clinical development-driven business model, and substantial funding, CStone’s vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
For more information about CStone Pharmaceuticals, please visit: www.cstonepharma.com.

Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas. With the launch of the world’s first PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), Ono is a pioneer in the field of immuno-oncology. For more information, please visit the company’s website at www.ono.co.jp.

Kaken Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd. is a specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery. The Company concentrates its R&D resources in inflammation/immunology (dermatitis, rheumatoid arthritis and osteoarthritis), pain relief and fungal infection areas.

For more information, please visit www.kaken.co.jp

 

Tillotts Pharma AG

Tillotts Pharma AG, part of the Zeria Group, is a fast-growing specialty pharma company with 200 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialization of innovative pharmaceutical products, medical devices and diagnostics, all in the field of gastroenterology. Tillotts successfully markets its own products Asacol® and Colpermin® as well as in-licensed products, such as Simtomax®, in over 55 countries through its own affiliates within Europe and a carefully chosen network of gastroenterology-focused marketing partners throughout the world. For more information please visit www.tillotts.com.

Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.
Accept